Nature research shows: BGM0504 developed with the help of artificial intelligence and molecular dynamics has excellent efficacy

2024-07-22 16:53:56

Shanghai (ots/PRNewswire) – The molecular design strategy and experimental results of Bright Gene’s GLP-1/GIP dual receptor agonist BGM0504 were published online on July 19, 2024 in Scientific Reports, a journal published by Nature Research. Bright Gene (stock code: 688166.SH) is an innovative international emerging pharmaceutical company focused on developing first-in-class medicines to improve the health of patients around the world.

The article titled “Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism against diabetes and obesity” introduces the development results of BGM0504.

BGM0504 is a dual GIP and GLP-1 receptor agonist developed by artificial intelligence. in vitro and in in vivo-Experimental results are excellent. Through artificial intelligence-driven computer simulations, Bright Gene discovered that optimal interactions between glutamate residues on GLP-1R and GIPR and the K20 residue of peptide agonists provide superior activity. This interaction is an important finding but was not evident in cryo-EM studies. BGM0504 was designed to retain the free amino group of the K20 residue by moving the acylation point to position 40 of BGM0504. This design tripled the agonist effects of GLP-1R and GIPR, with excellent therapeutic effects in mouse models of diabetes and obesity.

Information about Bright Gene and BGM0504

Bright Gene (stock code: 688166.SH) is an innovative pharmaceutical company focusing on the research and development of first-class drugs. The company integrates active ingredients and formulations, combining generic and innovative medicines to meet global clinical needs. BGM0504 is a dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes, obesity and NASH and is currently in late-stage Phase II clinical trials.

refer to

Yuan Jie, Liu Wen, Jiang X, et al. Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism against diabetes and obesity. Scientific Reports 14, 16680 (2024).

photo –

See original content:

Questions and contact information:

Cecelia Hu,
[e-mail]

1721674539
#Nature #research #shows #BGM0504 #developed #artificial #intelligence #molecular #dynamics #excellent #efficacy